Alpha Cognition Inc V.ACOG

Primary Symbol: C.ACOG Alternate Symbol(s): ACOGF

Healthcare Biotechnology

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.

CSE:ACOG - Post by User

Alpha Cognition Inc

<< Previous

Bullboard Posts

Next >>

Post by firstandgoal43on Mar 21, 2022 12:47pm

170 Views

Post# 34531707

$ACOG - Life Sci Conferences Bump

$ACOG SP Bump after the Life Sciences Conference

Raymond James Capital has given Alpha Cognition an “Outperform” rating with a new target price of 3.50. Positive PR from the conference has given way to a small bump in SP and should continue to grow. Volume is growing at a steady rate and investors are seemingly in for the long-run at this point.

$ACOGF $ACOG - Current SP: 1.09

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for April 25, 2024